February 2016

INVESTOR PRESENTATION

DISCLAIMER

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts

are forward-looking statements. The Company makes forward-looking public statements concerning its expected future

financial position, results of operations, cash flows, financing plans, business strategy, products and services, evaluation

of medical marijuana projects, alternative health projects or products, and cannabidiol-fortified products or services for

participation and/or financing, competitive positions, growth opportunities, plans and objectives of management for future

operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect,"

"intend," "may," "could," "should," "will," and other similar expressions that are forward-looking statements. Such forward-

looking statements are estimates reflecting the Company's best judgment based upon current information and involve a

number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such

forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the

2

forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the

interest rates on borrowings; whether or not the Company will be successful in executing its business plan in whole or in

part; hedging activities; changes in commodity prices; changes in the marketing or capital project expenditure levels;

litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Lexaria

Corp. operates. These and other risks and uncertainties are more fully described in our periodic reports and other

disclosure documents filed by Lexaria Corp. from time to time with regulatory authorities available on SEDAR at

www.sedar.com and on EDGAR at www.sec.gov, and the reader is encouraged to review these documents. Planned

dates stated herein are estimates only, based on best information available. Dates are not assured and are subject to

revision without notice. The Company assumes no obligation, except as required by law, to update any forward-looking

statement, whether as a result of new information, future events or otherwise. This presentation is not an offer to sell or a

solicitation of an offer to buy securities of Lexaria Corp. It is a short summary of certain information for introductory

purposes only and is not to be relied upon for investment purposes. No statement within has been evaluated by the

Food and Drug Administration, and no product or service is intended to diagnose, treat, cure or prevent any

disease.

PROBLEM

100%in…

Edible cannabinoids are the most popular method of consumption by consumers, butthey are poorly absorbed by our system(1)

3(1) Karschner et al. (2011) Clin. Chem. 57:66-75

94%+...out

SOLUTION

Our PATENT-PENDING LIPID-BASED DELIVERY TECHNOLOGY FOR EDIBLES allows for maximum absorption of cannabinoids through the convenience of edibles

We combine cannabinoids with

fatty acids at a molecular level

AND use a proprietary process

Flavor masking effects when ingested

4

AND use a proprietary process

for enhanced palatability and

bioabsorption in the intestines

Fatty acids are well absorbed in small intestine

� We are a food biosciences and consumer goods company

� We use our scientifically proven, patent-pending

technology to enable improved intestinal bioabsorption of

cannabinoids like cannabidiol (CBD) and

OUR FOCUS

5

cannabinoids like cannabidiol (CBD) and

tetrahydrocannabinol (THC); also applicable to a host of

other bioactive substances

� We are currently focused on the development and sale of

CBD-rich, hemp-oil infused foods and beverages; federally

legal for sale nationwide in the U.S. and many other

countries

Our Patents Pending Cover:

• Coffee & Tea

• Hot Chocolate

• Meats

• Gum Arabic

For the Delivery of:

• CBD & THC

• Vitamins

• Acetaminophen

• Ibuprofen

SIX PATENTS PENDING

6

• Gum Arabic

• Cookies, Breads, etc

• Fruits & Nuts

• Carbonated beverages

• Fruit & Dairy beverages

• Tapioca Starch

• …and more

• Ibuprofen

• Acetylsalicylic acid (ASA)

• Diclofenac, Indomethacin

• Piroxicam

• NICOTINE

PRODUCT PORTFOLIO

7

ViPova™ CBD-Infused

Hot Beverages

Lexaria Energy CBD-Infused

Protein-Energy Bars

� Potent activator of human endocannabinoid system

� Relieves pain and inflammation

� Combats anxiety / promotes better focus and

THERE ARE MANY MEDICINAL BENEFITS OF CANNABIDIOL

8

� Combats anxiety / promotes better focus and

concentration

� Enhances vascular blood flow and performance

� Potent antioxidant

� In vitro study

� Third-party laboratory

� Human small intestine tissues

% P

erm

eab

ilit

y A

cro

ss T

issu

e M

em

bra

ne

325%Improvement499%

CANNABIDIOL HUMAN INTESTINAL BIOABSORPTION STUDY

9

� Matching CBD content per group

� Simulated intestinal fluid buffer applied to all groups

% P

erm

eab

ilit

y A

cro

ss T

issu

e M

em

bra

ne

ViPova™ CBD-Infused

Black Tea

CBD

Black Tea

Control Group 2

CBD

Water

Control Group 1

325%Improvement499%

Improvement

� Recent study demonstrated potent CBD

bioabsorption in human subjects using

nitric oxide salivary biomarker test

� Tested ViPova™ Teas, Coffee and Hot

Chocolate, as well as Lexaria Energy Foods

HUMAN CLINICAL NITRIC OXIDE INDUCTION STUDY

10

Chocolate, as well as Lexaria Energy Foods

Protein Bars

� All subjects demonstrated rapid, significant

and sustained increase in salivary nitric

oxide levels following product ingestion

� Findings have significant implications for

health and fitness consumers

� 1998 Nobel Prize discovery that nitric

oxide is responsible for dilation of

blood vessels (vasodilation)

� In theory, consumption of a Lexaria

food products utilizing our technology

� Involved in neurodegenerative

disorders such as dementia

� Utilized by white blood cells as a

weapon against bacteria, fungi,

parasites and more

NITRIC OXIDE MEDICINAL RELEVANCE

11

food products utilizing our technology

will allow for more open blood

vessels, delivering more nutrients and

oxygen to muscles and organs;

MARKETING ADVANTAGE for fitness

consumers

parasites and more

� Involved in intestinal peristalsis;

insulin signaling, bone remodeling,

respiratory function, and more

� Can reduce blood pressure

Launched

ViPova™

CBD-Black Tea

Wholesale

Sales Efforts

Begin

Added

Six New

ViPova™

Tea Flavors

ViPova™

CBD-Coffee

and Cocoa

Launch

Distribution

Agreements

Initiated

KEY MILESTONES

12

Q1, 2015 Q2, 2015 Q3, 2015 Q4, 2015

Lexaria Energy

Protein Bar Launch

Q1, 2016 Q2, 2016

Begin Chain Purchasing

Manager Outreach

WA

NV

MN

PA

NY

MAMI

GROWING NATIONWIDE SALES

13

SC

GAALMS

TX

CO

AZ

NV

CA

FL

NCTN

KY

IL

PAOH

MD

U.S. GROWTH TARGET EXAMPLES

70,000+ Pharmacies 168,000+ Gas Stations

40,000+ Fitness Centers

14

150,000+ Convenience Stores53,000+ Coffee Shops

15,000+ Wellness Stores

….and more…..

� Each Lexaria sales channel is different and demands unique

strategies / generates unique returns.

� Hemp oil-inclusive food products are federally legal and easily

distributed.

� Many “convenience foods” such as standard protein bars sell $50

Up To 650,000 Existing Retail Stores Could Carry Our Products

15

� Many “convenience foods” such as standard protein bars sell $50

- $75 per location, per week.

� Our goal is to have our products available in 10% of them within 5

years.

� Telluride Coffee-House distribution

to over 100 Colorado locations

began February 2016

DISTRIBUTION AGREEMENTS INITIATED

16

began February 2016

� Other distribution partnerships

under development in U.S. and

internationally

OUT-LICENSING OPPORTUNITIES

� Evaluating license partners for our technology

� For example: THC edible companies

� Plan to perform in vitro / in vivo analysis on the molecules

named below, to enhance value of potential licensing /

17

named below, to enhance value of potential licensing /

partnering

� Other compounds named in patent filings beyond

cannabinoids:

• Nicotine

• NSAIDs (e.g., ASA, ibuprofen, etc.)

• Vitamins (e.g., vitamin E)

• Current markets for these compounds = $1 trillion

Debt or Equity

• Equity with warrant

• 4-5 year convertible

debenture with varied future

Use of Proceeds

• Expand distribution and sales

• Increase production

• Develop additional I.P. through

CAPITAL REQUIREMENTS

18

conversion price, with floor proprietary R&D

• Perform new product

development

• Perform additional in vitro /

in vivo testing

�� Chairman & CEOChairman & CEO: : Chris Bunka Chris Bunka -- 20+ years Entrepreneur20+ years Entrepreneur

�� President: President: John Docherty, John Docherty, MSc MSc -- BioPharmaBioPharma ExecutiveExecutive

�� CFO: CFO: Bal Bhullar, Bal Bhullar, CPA, CGACPA, CGA, CRM , CRM -- 20+ years Risk 20+ years Risk

THE RIGHT PEOPLE

19

�� CFO: CFO: Bal Bhullar, Bal Bhullar, CPA, CGACPA, CGA, CRM , CRM -- 20+ years Risk 20+ years Risk ManagementManagement

�� Executive VP: Executive VP: Tom Tom IhrkeIhrke, MBA , MBA -- Banking, Finance ExpertBanking, Finance Expert

�� Director: Director: Ted Ted McKechnieMcKechnie -- Past President $3 Billion Maple Past President $3 Billion Maple Leaf Foods, Kraft, PepsiCo.Leaf Foods, Kraft, PepsiCo.

Share Structure @ Feb 1, 2016

Issued & Outstanding

44,553,286

Stock Symbols OTCQB: LXRPCSE: LXX

Stock Performance @ Feb 1, 2016

SHARE STRUCTURE AND PERFORMANCE

20

Outstanding

Warrants 7,920,586

Options 4,125,000

Fully Diluted 56,598,872

Performance

Share Price US$0.11

52 Week Hi-Lo $0.066-$0.28

Avg. Daily Volume (shares)

100,000 (OTCQB)40,000 (CSE)

Market Cap. ~$5.0MM

950, 1130 W. Pender St.Vancouver, BC V6E 4A4604 602 1675

Chris Bunka

Contact Information

Chris Bunka250 765 6424bossbunka@gmail.com

www.LexariaEnergy.com